CAMBRIDGE, Mass., Feb. 9 /PRNewswire/ -- Archemix Corp., the privately- held biopharmaceutical company focused on discovering and developing aptamer- based therapeutics, announced today that the company has moved into a new facility in Cambridge, Massachusetts, to allow for accelerated growth and expansion. The facility encompasses 35,000 square feet of research and development and office space. All Archemix corporate phone numbers will remain the same including the main phone number 617-621-7700. The new address is 300 Third Street, Cambridge, MA 02139.
"Our decision to remain in Cambridge amongst some of the world's leading biotechnology companies and academic centers reflects our commitment to scientific excellence," said Dr. Errol De Souza, President and Chief Executive Officer of Archemix. "As Archemix grows, so too has our need for expanded facilities that can keep pace with the progress of our development pipeline. The new building confirms our commitment to excellence in science and medicine by placing our research functions at its core."
About Aptamers
Aptamers are single-stranded nucleic acids that form well-defined three- dimensional shapes, allowing them to bind to target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical and biological stability, low immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed, offering a significant cost advantage. As therapeutic agents, aptamers have demonstrated clinical biological efficacy and have excellent, tunable pharmacokinetic properties.
About Archemix Corp.
Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge, Massachusetts. The company's mission is to develop aptamers as a class of directed therapeutics for the treatment of human disease. Because of their unique properties and proven efficacy, aptamers are a superior alternative to biologics and small molecules and will be a major class of drugs for the treatment of unmet medical needs.
Archemix's aptamer expertise is complemented by a dominant patent estate comprised of over 220 issued and 230 pending patents covering the identification, composition and use of therapeutic aptamers. In addition to the company's core aptamer generation technology, Archemix possesses strong expertise in both preclinical and clinical drug development. Further information about Archemix can be found at http://www.archemix.com.
For further information or to speak with Dr. Errol De Souza, please contact Davia Temin of Temin and Company at 212-588-8788 or news@teminandco.com.
Archemix Corp.CONTACT: Davia Temin of Temin and Company, +1-212-588-8788,news@teminandco.com, for Archemix Corp.
Web site: http://www.archemix.com/
